无事件生存期作为初治急性髓系白血病稳健终点的评估
研究纳入5项Alliance临床试验中1884例接受蒽环类和阿糖胞苷诱导化疗的初治AML患者,评估EFS作为终点的稳健性,重点关注完全缓解(CR)时机定义诱导失败及造血干细胞移植(HCT)的影响。结果显示,HCT时删失对EFS估计影响极小,但CR时机定义诱导失败可显著改变中位EFS估计,多数情况下差异足以导致单臂试验得出错误疗效结论。
要点
- HCT时删失对EFS估计影响极小。
- CR时机定义诱导失败可显著改变中位EFS估计。
- CR时机差异多数情况下足以导致单臂试验错误结论。
核心结论
- HCT时删失对EFS估计影响极小,但CR时机定义诱导失败可显著改变中位EFS估计,差异足以在多数情况下导致单臂试验得出错误疗效结论。
- 使用EFS作为主要终点的单臂试验设计时,应仔细检查历史对照数据中CR时机的定义。
研究设计与样本
- 研究纳入通过Alliance for Clinical Trials in Oncology开展的5项试验中1884例初治AML患者,均接受蒽环类和阿糖胞苷诱导化疗。
- EFS定义为从随机化/注册至诱导失败、复发或死亡的时间。
- 评估三种诱导失败定义:随机化/注册后60天未达CR、所有方案定义诱导疗程结束未达CR、所有方案定义治疗结束未达CR。
- 考虑非方案强制HCT时删失或不删失两种情况。
主要发现
- 复发和死亡是硬终点,但诱导失败的判定在各研究间不一致。
- HCT时删失对EFS估计影响极小。
- 中位EFS估计因CR时机定义诱导失败而差异显著,多数情况下差异足以导致单臂试验错误结论。
临床怎么用
- 使用EFS作为主要终点的单臂试验设计时,应仔细检查历史对照数据中CR时机的定义。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Event-free survival (EFS) is controversial as an end point for speeding approvals in newly diagnosed acute myeloid leukemia (AML). We aimed to examine the robustness of EFS, specifically timing of complete remission (CR) in defining induction failure and impact of hematopoietic cell transplantation (HCT). The study included 1884 untreated AML patients enrolled across 5 trials conducted through Alliance for Clinical Trials in Oncology using anthracycline and cytarabine induction chemotherapy. EFS was defined as time from randomization/registration to induction failure, relapse, or death. Three definitions of induction failure were evaluated: failure to achieve CR by 60 days after randomization/registration, failure to achieve CR by the end of all protocol-defined induction courses, and failure to achieve CR by the end of all protocol-defined treatment. We considered either censoring or no censoring at time of non-protocol-mandated HCT. Although relapse and death are firm end points, the determination of induction failure was not consistent across studies. There was minimal impact of censoring at HCT on EFS estimates; however, median EFS estimates differed considerably based on the timing of CR in defining induction failure, with the magnitude of difference being large enough in most cases to lead to incorrect conclusions about efficacy in a single-arm trial, if the trial definition was not consistent with the definition used for the historical control. Timing of CR should be carefully examined in the historical control data used to guide the design of single-arm trials using EFS as the primary end point. Trials were registered at www.clinicaltrials.gov as #NCT00085124, #NCT00416598, # NCT00651261, #NCT01238211, and #NCT01253070.
引用
- Yin J, LaPlant B, Uy GL, et al. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019. PMID: 31171508. doi:10.1182/bloodadvances.2018026112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。